Update in tuberculosis 2008

American Journal of Respiratory and Critical Care Medicine

Volumn 179, Issue 5, 2009, Pages 337-343

  Yew, Wing Wai ^a   Leung, Chi Chiu ^b  

^a GRANTHAM HOSPITAL   (Hong Kong)

^b DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BCG VACCINE; CAPREOMYCIN; CYCLOSERINE; CYTOKINE; DNA VACCINE; ISONIAZID; LINEZOLID; MATRIX METALLOPROTEINASE; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIGEN PRESENTATION; CHROMOSOME 20Q; CHROMOSOME 6P; CLINICAL TRIAL; CYTOKINE PRODUCTION; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG DOSE REDUCTION; ETHNICITY; GENETIC SUSCEPTIBILITY; GENOTYPE; HEMATOLOGIC DISEASE; HUMAN; LIVER TOXICITY; LUNG LAVAGE; MORBIDITY; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; NEUROTOXICITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; TUBERCULIN TEST; TUBERCULOSIS; ANIMAL; GENETICS; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 63349096910     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200812-1852UP     Document Type: Review

References (55)

1. Cooke GS, Campbell SJ, Bennett S, Lienhardt C, McAdam KP, Sirugo G, Sow O, Gustafson P, Mwangulu F, van Helden P, et al. Mapping of a novel susceptibility locus suggests a role for MC3R and CTSZ in human tuberculosis. Am J Respir Crit Care Med 2008;178:203-207.
2. Selvaraj P, Alagarasu K, Harishankar M, Vidyarani M, Nisha Rajeswari D, Narayanan PR. Cytokine gene polymorphisms and cytokine levels in pulmonary tuberculosis. Cytokine 2008;43:26-33.
3. Chang ST, Linderman JJ, Kirschner DE. Effect of multiple genetic polymorphisms on antigen presentation and susceptibility to Mycobacterium tuberculosis infection. Infect Immun 2008;76:3221-3232.
4. Elkington PT, Nuttall RK, Boyle JJ, O'Kane CM, Horncastle DE, Edwards DR, Friedland JS. Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am J Respir Crit Care Med 2005;172:1596-1604.
5. Elkington PT, Green JA, Emerson JE, Lopez-Pascua LD, Boyle JJ, O'Kane CM, Friedland JS. Synergistic up-regulation of epithelial cell matrix metalloproteinase-9 secretion in tuberculosis. Am J Respir Cell Mol Biol 2007;37:431-437.
6. O'Kane CM, Elkington PT, Friedland JS. Monocyte-dependent oncostatin M and TNF-alpha synergize to stimulate unopposed matrix metalloproteinase-1/3 secretion from human lung fibroblasts in tuberculosis. Eur J Immunol 2008;38:1321-1330.
7. Dou J, Tang Q, Zhao F, Chu L, Chen J, Cao M, Liu C, Wang Y, Li Y, Li JL. Comparison of immune responses induced in mice by vaccination with DNA vaccine constructs expressing mycobacterial antigen 85A and interleukin-21 and Bacillus Calmette-Guerin. Immunol Invest 2008;37:113-127.
8. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, Aagaard C, Werninghaus K, Kirschning C, Lang R, Christensen D, et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 2008;3:e3116.
9. Pires A, Nelson M, Pozniak AL, Fisher M, Gazzard B, Gotch F, Imami N. Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy. J Immune Based Ther Vaccines 2005;3:7.
10. Meintjes G, Wilkinson KA, Rangaka MX, Skolimowska K, van Veen K, Abrahams M, Seldon R, Pepper DJ, Rebe K, Mouton P, et al. TH1 and FoxP3-positive T cells in HIV-tuberculosis immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008;178:1083-1089.
11. Dowdle WR. Centers for Disease Control (CDC). A strategic plan for the elimination of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep 1989;38(Suppl 3):1-25.
12. Khan K, Wang J, Hu W, Bierman A, Li Y, Gardam M. Tuberculosis infection in the United States: national trends over three decades. Am J Respir Crit Care Med 2008;177:455-460.
13. Bennett DE, Courval JM, Onorato I, Agerton T, Gibson JD, Lambert L, McQuillan GM, Lewis B, Navin TR, Castro KG. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999 - 2000. Am J Respir Crit Care Med 2008;177:348-355.
14. Bailey WC, Gerald LB, Kimerling ME, Redden D, Brook N, Bruce F, Tang S, Duncan S, Brooks CM, Dunlap NE. Predictive model to identify positive tuberculosis skin test results during contact investigations. JAMA 2002;287:996-1002.
15. Aissa K, Madhi F, Ronsin N, Delarocque F, Lecuyer A, Decludt B, Remus N, Abel L, Poirier C, Delacourt C; CG94 Study Group. Evaluation of a model for efficient screening of tuberculosis contact subjects. Am J Respir Crit Care Med 2008;177:1041-1047.
16. Mancuso JD, Tobler SK, Keep LW. Pseudoepidemics of tuberculin skin test conversions in the US Army after recent deployments. Am J Respir Crit Care Med 2008;177:1285-1289.
17. Borgdorff MW, Nagelkerke NJ, de Haas PE, van Soolingen D. Transmission of Mycobacterium tuberculosis depending on the age and sex of source cases. Am J Epidemiol 2001;154:934-943.
18. Kik SV, Verver S, van Soolingen D, de Haas PE, Cobelens FG, Kremer K, van Deutekom H, Borgdorff MW. Tuberculosis outbreaks predicted by characteristics of first patients in a DNA fingerprint cluster. Am J Respir Crit Care Med 2008;178:96-104.
19. Leung CC, Lam TH, Chan WM, Yew WW, Ho KS, Leung GM, Law WS, Tam CM, Chan CK, Chang KC. Diabetic control and risk of tuberculosis: a cohort study. Am J Epidemiol 2008;167:1486-1494.
20. Kim RD, Greenberg DE, Ehrmantraut ME, Ding L, Shea Y, Chernick M, Jolley C, Raffeld M, Avila N, Sachdev V, et al. Pulmonary non-tuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008;178:1066-1074.
21. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole-blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008;177:1164-1170.
22. Dosanjh DP, Hinks TS, Innes JA, Deeks JJ, Pasvol G, Hackforth S, Varia H, Millington KA, Gunatheesan R, Guyot-Revol V, et al. Improved diagnostic evaluation of suspected tuberculosis. Ann Intern Med 2008;148:325-336.
23. Higuchi K, Harada N, Fukazawa K, Mori T. Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis. Tuberculosis (Edinb) 2008;88:244-248.
24. Breen RA, Barry SM, Smith CJ, Shorten RJ, Dilworth JP, Cropley I, McHugh TD, Gillespie SH, Janossy G, Lipman MC. Clinical application of a rapid lung-orientated immunoassay in individuals with possible tuberculosis. Thorax 2008;63:67-71.
25. Campos M, Quartin A, Mendes E, Abreu A, Gurevich S, Echarte L, Ferreira T, Cleary T, Hollender E, Ashkin D. Feasibility of shortening respiratory isolation with a single sputum nucleic acid amplification test. Am J Respir Crit Care Med 2008;178:300-305.
26. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008;177:787-792.
27. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008;32:1165-1174.
28. dos Santos RP, Scheid KL, Willers DM, Goldani LZ. Comparative radiological features of disseminated disease due to Mycobacterium tuberculosis vs non-tuberculosis mycobacteria among AIDS patients in Brazil. BMC Infect Dis 2008;8:24.
29. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al.; ATS Mycobacterial Diseases Subcommittee. An Official ATS/IDSA Statement: Diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
30. Kitada S, Kobayashi K, Ichiyama S, Takakura S, Sakatani M, Suzuki K, Takashima T, Nagai T, Sakurabayashi I, Ito M, et al., for the MAC Serodiagnosis Study Group. Serodiagnosis of Mycobacterium avium complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med 2008;177:793-797.
31. Chang KC, Leung CC, Yew WW, Lau TY, Tam CM. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 2008;177:1391-1396.
32. Mak A, Thomas A, del Granado M, Zaleskis R, Mouzafarova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008;178:306-312.
33. Centers for Disease Control and Prevention (CDC). Extensively drug-resistant tuberculosis - United States 1993 - 2006. MMWR Morb Mortal Wkly Rep 2007;56:250-253.
34. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, Lee JK, Kim SJ. Trend of anti-tuberculosis drug resistance in Korea, 1994 - 2004. Int J Tuberc Lung Dis 2007;11:571-576.
35. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008;47:496-502.
36. Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC, Lee H, Eum SY, Jeon DS, Kang HS, Kim JH, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008;46:42-49.
37. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008;178:1075-1082.
38. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Viru FA, Appleton SC, Bayona JN, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008;359:563-574.
39. Migliori GB, Lange C, Centis R, Sotgiu G, Mutterlein R, Hoffmann H, Kliiman K, De Iaco G, Lauria FN, Richardson MD, et al., TBNET Study Group. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008;31:1155-1159.
40. O'Brien RJ, Spigelman M. New drugs for tuberculosis: current status and future prospects. Clin Chest Med 2005;26:327-340.
41. Spigelman MK. New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007;196(Suppl 1):S28-S34.
42. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4:e344.
43. Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 2008;178:989-993.
44. Alcalá L, Ruiz-Serrano MJ, Pérez-Fernández Turégano C, García De Viedma D, Díaz-Infantes M, Marín-Arriaza M, Bouza E. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 2003;47:416-417.
45. Fortun J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, De la Pedrosa EG, Gomez-Mampaso E, Moreno S. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005;56:180-185.
46. Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006;58:701-704.
47. Dietze R, Hadad DJ, McGee B, Molino LP, Maciel EL, Peloquin CA, Johnson DF, Debanne SM, Eisenach K, Boom WH, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008;178:1180-1185.
48. Louie A, Heine HS, Kim K, Brown DL, VanScoy B, Liu W, Kinzig-Schippers M, Sorgel F, Drusano GL. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother 2008;52:2486-2496.
49. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-227.
50. Lounis N, Gevers T, Van Den Berg J, Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother 2008;52:3568-3572.
51. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, De Marez T, van Heeswijk R, Kerstens R, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:2831-2835.
52. Veziris N, Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 2009;179:75-79.
53. Nuermberger E, Mitchison DA. Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility. Am J Respir Crit Care Med 2009;179:2-3.
54. Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in the murine model of tuberculosis. Antimicrob Agents Chemother 2008;52:3664-3668.
55. Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008;52:1522-1524.